Bibliografia studi

Bibliografia studi

Di seguito viene elencata la bibliografia degli studi citati nel sito. È possibile consultare integralmente ogni studio sulla piattaforma/rivista dov’è stato originariamente caricato cliccando sul link azzurro in base alle preferenze. L’elenco è in continuo aggiornamento.

Sei un medico o un ricercatore e desideri metterti in contatto con Kaqun? Clicca qui

  • Joan Khoo, Christoph E. Hagemeyer, Darren C. Henstridge. Effects of water stably-enriched with oxygen as a novel method of tissue oxygenation on mitochondrial function, and as adjuvant therapy for type 2 diabetes in a randomized placebo-controlled trial. 2021,  0254619
    PlosONE

  • Mennerich D, Kubaichuk K, Kietzmann T. DUBs, Hypoxia, and Cancer. Trends Cancer. 2019;5(10):632–53.
    CAS – PubMed – Article – Google Scholar 

  • Wang J, Ni Z, Duan Z, Wang G, Li F. Altered expression of hypoxia-inducible factor-1α (HIF-1α) and its regulatory genes in gastric cancer tissues. PloS ONE. 2014;9:e99835.
    PubMed –  PubMed Central – Article – CAS – Google Scholar 

  • Zhang Z, Yao L, Yang J, Wang Z, Du G. PI3K/Akt and HIF-1 signaling pathway in hypoxia-ischemia. Mol Med Rep. 2018;18:3547–54.
    CAS – PubMed – PubMed Central – Google Scholar 

  • Al Tameemi W, Dale TP, Al-Jumaily RMK, Forsyth NR. Hypoxia-modified cancer cell metabolism. Front Cell Dev Biol. 2019;7:4.
    PubMed – PubMed Central – Article – Google Scholar 

  • García-Pastor C, Benito-Martínez S, Moreno-Manzano V, Fernández-Martínez AB, Lucio-Cazaña FJ. Mechanism and consequences of the impaired Hif-1α response to hypoxia in human proximal tubular HK-2 cells exposed to high glucose. Sci Rep. 2019;9:15868.
    PubMed – PubMed Central – Article – CAS – Google Scholar 

  • Al Qahtani A, Holly J, Perks C. Hypoxia negates hyperglycaemia-induced chemo-resistance in breast cancer cells: the role of insulin-like growth factor binding protein 2. Oncotarget. 2017;8:74635–48.
    PubMed – PubMed Central – Article – Google Scholar 

  • Görgens SW, Benninghoff T, Eckardt K, Springer C, Chadt A, Melior A, et al. Hypoxia in combination with muscle contraction improves insulin action and glucose metabolism in human skeletal muscle via the HIF-1α pathway. Diabetes. 2017;66:2800–7.
    PubMed – Article – CAS – PubMed Central – Google Scholar 

  • Triner D, Shah YM. Hypoxia-inducible factors: a central link between inflammation and cancer. J Clin Invest. 2016;126:3689–98.
    PubMed – PubMed Central – Article – Google Scholar 

  • Han S, Huang T, Hou F, Yao L, Wang X, Wu X. The prognostic value of hypoxia-inducible factor-1α in advanced cancer survivors: a meta-analysis with trial sequential analysis. Ther Adv Med Oncol. 2019;11:1758835919875854
    CAS – PubMed – PubMed Central – Google Scholar

  • Krutilina R, Sun W, Sethuraman A, Brown M, Seagroves TN, Pfeffer LM, et al. MicroRNA-18a inhibits hypoxia-inducible factor 1α activity and lung metastasis in basal breast cancers. Breast Cancer Res. 2014;16:R78.
    PubMed – PubMed Central – Article – CAS – Google Scholar 

  • Rohwer N, Cramer T: Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 2011, 14 (3): 191-201. 10.1016/j.drup.2011.03.001.
    CAS – Article – PubMed – Google Scholar

     

  • Bento CF, Pereira P. Regulation of hypoxia-inducible factor 1 and the loss of the cellular response to hypoxia in diabetes. Diabetologia. 2011;54:1946–56.

    CAS–  PubMed – Article – Google Scholar 

  • Rohwer N, Dame C, Haugstetter A, Wiedenmann B, Detjen K, Schmitt CA, Cramer T: Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS One. 2010, 5 (8): e12038-10.1371/journal.pone.0012038.
    Article –  PubMed –  PubMed Central – Google Scholar

  • Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey IB, Choyke P, Murgo AJ, Doroshow JH, Melillo G: Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1alpha in advanced solid tumors. Clin Cancer Res. 2011, 17 (15): 5123-5131. 10.1158/1078-0432.CCR-11-0682.
    CAS – Article – PubMed – PubMed Central – Google Scholar

  • Partridge SE, Aquino-Parsons C, Luo C, Green A, Olive PL: A pilot study comparing intratumoral oxygenation using the comet assay following 2.5% and 5% carbogen and 100% oxygen. Int J Radiat Oncol Biol Phys. 2001, 49 (2): 575-580. 10.1016/S0360-3016(00)01504-2.
    CAS – Article – PubMed – Google Scholar

  • Evans SM, Hahn SM, Magarelli DP, Koch CJ: Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol. 2001, 24 (5): 467-472. 10.1097/00000421-200110000-00011.
    CAS – Article –  PubMed – Google Scholar

  • Brahimi-Horn MC, Chiche J, Pouyssegur J: Hypoxia and cancer. J Mol Med. 2007, 85 (12): 1301-1307. 10.1007/s00109-007-0281-
    Article – PubMed –  Google Scholar

  • Zhou J, Schmid T, Schnitzer S, Brune B: Tumor hypoxia and cancer progression. Cancer Lett. 2006, 237 (1): 10-21. 10.1016/j.canlet.2005.05.02
    CAS – Article – PubMed  – Google Scholar

  • Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009, 324 (5930): 1029-1033. 10.1126/science.1160809.
    CAS – Article – PubMed PubMed Central – Google Scholar

  • Brown JM, Wilson WR: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004, 4 (6): 437-447. 10.1038/nrc1367.
    CAS – Article – PubMed – Google Scholar

  • Wartenberg M, Ling FC, Muschen M, Klein F, Acker H, Gassmann M, Petrat K, Putz V, Hescheler J, Sauer H: Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J. 2003, 17 (3): 503-505.
    CAS – PubMed – Google Scholar

  • Matzow T, Cowen RL, Williams KJ, Telfer BA, Flint PJ, Southgate TD, Saunders MP: Hypoxia-targeted over-expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT-11). J Gene Med. 2007, 9 (4): 244-252. 10.1002/jgm.1016.
    CAS – Article – PubMed – Google Scholar

  • Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C, Stratford IJ, Dive C: Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol. 2004, 24 (7): 2875-2889. 10.1128/MCB.24.7.2875-2889.2004.
    CAS – Article – PubMed – PubMed Central – Google Scholar

  • Kim JY, Kim YJ, Lee S, Park JH: The critical role of ERK in death resistance and invasiveness of hypoxia-selected glioblastoma cells. BMC Cancer. 2009, 9: 27-10.1186/1471-2407-9-27.
    Article – PubMed – PubMed Central – Google Scholar

  • Baumann RP, Penketh PG, Seow HA, Shyam K, Sartorelli AC: Generation of oxygen deficiency in cell culture using a two-enzyme system to evaluate agents targeting hypoxic tumor cells. Radiat Res. 2008, 170 (5): 651-660. 10.1667/RR1431.1.
    CAS – Article – PubMed PubMed Central – Google Scholar

  • Minchinton AI, Tannock IF: Drug penetration in solid tumours. Nat Rev Cancer. 2006, 6 (8): 583-592. 10.1038/nrc1893.
    CAS – Article –  PubMed – Google Scholar

  • Hay MP, Gamage SA, Kovacs MS, Pruijn FB, Anderson RF, Patterson AV, Wilson WR, Brown JM, Denny WA: Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J Med Chem. 2003, 46 (1): 169-182. 10.1021/jm020367+
    CAS – Article – PubMed – Google Scholar

  • Shin DH, Chun YS, Lee DS, Huang LE, Park JW: Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood. 2008, 111 (6): 3131-3136. 10.1182/blood-2007-11-120576.
    CAS – Article – PubMed –Google Scholar

  • Duyndam MC, van Berkel MP, Dorsman JC, Rockx DA, Pinedo HM, Boven E: Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. Biochem Pharmacol. 2007, 74 (2): 191-201. 10.1016/j.bcp.2007.04.003.
    CAS – Article – PubMed – Google Scholar

  • Escuin D, Kline ER, Giannakakou P: Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res. 2005, 65 (19): 9021-9028. 10.1158/0008-5472.CAN-04-4095.
    CAS – Article – PubMed – Google Scholar

  • Forde JC, Perry AS, Brennan K, Martin LM, Lawler MP, Lynch TH, Hollywood D, Marignol L: Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells. Urol Oncol. 2010, 30: 912-919.
    Article –  PubMed – Google Scholar

  • Sermeus A, Cosse JP, Crespin M, Mainfroid V, de Longueville F, Ninane N, Raes M, Remacle J, Michiels C: Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity. Mol Cancer. 2008, 7: 27-
    Article –  PubMed – PubMed Central – Google Scholar

  • Sullivan R, Graham CH: Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. Mol Cancer Ther. 2009, 8 (6): 1702-1713. 10.1158/1535-7163.MCT-08-1090.
    CAS – Article – PubMed – Google Scholar

  • Onozuka H, Tsuchihara K, Esumi H: Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs. Cancer Sci. 2011, 102 (5): 975-982. 10.1111/j.1349-7006.2011.01880.x.
    CAS – Article – PubMed – Google Scholar

  • Kasuya K, Tsuchida A, Nagakawa Y, Suzuki M, Abe Y, Itoi T, Serizawa H, Nagao T, Shimazu M, Aoki T: Hypoxia-inducible factor-1alpha expression and gemcitabine chemotherapy for pancreatic cancer. Oncol Rep. 2011, 26 (6): 1399-1406.
    CAS – PubMed – Google Scholar

  • Kamiyama H, Takano S, Tsuboi K, Matsumura A: Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol. 2005, 131 (4): 205-213. 10.1007/s00432-004-0642-z.
    CAS – Article – PubMed – Google Scholar

  • Hu Y, Kirito K, Yoshida K, Mitsumori T, Nakajima K, Nozaki Y, Hamanaka S, Nagashima T, Kunitama M, Sakoe K, Komatsu N: Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Mol Cancer Ther. 2009, 8 (8): 2329-2338. 10.1158/1535-7163.MCT-09-0150.
    CAS – Article – PubMed – Google Scholar

  • Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT: Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002, 22 (20): 7004-7014. 10.1128/MCB.22.20.7004-7014.2002.
    CAS – Article – PubMed – PubMed Central – Google Scholar

  • Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C: BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 2002, 100 (10): 3767-3775. 10.1182/blood-2002-01-0109.
    CAS – Article – PubMed – Google Scholar

  • Pencreach E, Guerin E, Nicolet C, Lelong-Rebel I, Voegeli AC, Oudet P, Larsen AK, Gaub MP, Guenot D: Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin Cancer Res. 2009, 15 (4): 1297-1307. 10.1158/1078-0432.CCR-08-0889.
    CAS – Article – PubMed – Google Scholar

  • Reddy SB, Williamson SK: Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs. 2009, 18 (1): 77-87. 10.1517/13543780802567250.
    CAS – Article – PubMed – Google Scholar

  • Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH, Melillo G: Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 2002, 62 (15): 4316-4324.
    CAS – PubMed – Google Scholar

  • Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo C, Han S, Liu J, Sun S, Han Z, Wu K, Fan D: Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci. 2008, 99 (1): 121-128.
    CAS – PubMed – Google Scholar

  • Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM: Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem. 2006, 281 (22): 15215-15226. 10.1074/jbc.M511408200.
    CAS – Article – PubMed – Google Scholar

  • Vaupel P, Thews O, Hoeckel M: Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol. 2001, 18 (4): 243-259. 10.1385/MO:18:4:243.
    CAS – Article – PubMed – Google Scholar

  • Bensellam M, Duvillié B, Rybachuk G, Laybutt DR, Magnan C, Guiot Y, et al. Glucose-induced O2 consumption activates hypoxia inducible factors 1 and 2 in rat insulin-secreting pancreatic beta-cells. PLoS ONE. 2012;7:e29807.
    CAS – PubMed – PubMed Central – Article – Google Scholar 

  • Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia. 2015;3:83–92.
    PubMed –  PubMed Central – Article – Google Scholar 

  • Stegeman H, Span PN, Peeters WJ, Verheijen MM, Grénman R, Meijer TW, et al. Interaction between hypoxia, AKT and HIF-1 signaling in HNSCC and NSCLC: implications for future treatment strategies. Future Sci. 2016;2:84.
    Google Scholar